Claims
- 1. A tetrapeptide of the formula:
- Val-X-Ala-X,
- wherein Val is L-valine, the X between Val and Ala is 4-amino-3-hydroxy-6-methylheptanoyl and the other X is 4-amino-3-hydroxy-6-methylheptanoic acid or a salt or an ester thereof and Ala is L-alanine, the amino functionality of the X between Val and Ala being attached to the carbonyl functionality of Val to form an amido group, the carbonyl functionality of the X between Val and Ala being attached to the amino functionality of Ala to form an amido group and the amino functionality of the other X being attached to the carbonyl functionality of Ala to form an amido group, and N-acyl peptides of said tetrapeptide of the formula:
- R'-Val-X-Ala-X,
- wherein Val-X-Ala-X is as previously defined and R' is an acyl radical having 1 to 16 carbon atoms or said acyl radical partially substituted by one or more hydroxyl groups or halogen atoms or a C-Terminal of a lower alkyl ester, the carbonyl functionality of the unsubstituted or partially substituted acyl radical being attached to the amino functionality of Val to form an amido group.
- 2. An N-acyl peptide in accordance with claim 1 in which R' is lactoyl radical.
- 3. An N-acyl peptide in accordance with claim 1 in which R' is a member selected from the group consisting of formyl, acetyl, propionyl, n-butyryl, isobutyryl, n-valeryl, isovaleryl, n-caproyl, isocaproyl, n-heptanoyl, capryloyl, capryl, lauroyl, myristoyl, palmitoyl, stearoyl, arachidoyl, oleoyl, erucyl, linoleoyl, linolenoyl, .beta.-hydroxypropionyl, oxalyl, malonyl, benzoyl, cinnamoyl, phthaloyl, acryloyl, phenoxyacetyl and phenoxypropionyl residues.
- 4. A pharmaceutical composition for administration to humans and animals comprising an amount effective to reduce an otherwise abnormally high level of pepsin activity of a compound of claim 1 in combination with a pharmaceutically acceptable nontoxic carrier.
- 5. A method for chemotherapeutically treating humans and animals having a biochemical disorder characterized by an abnormally high level of pepsin activity which comprises administering a compound of claim 1 orally or intraperitoneally to said humans and animals in a dosage sufficient to lower said pepsin activity.
Priority Claims (6)
Number |
Date |
Country |
Kind |
51-1055 |
Jan 1976 |
JA |
|
49-23953 |
Feb 1974 |
JA |
|
49-28849 |
Mar 1974 |
JA |
|
49-40696 |
Apr 1974 |
JA |
|
49-145208 |
Dec 1974 |
JA |
|
49-146474 |
Dec 1974 |
JA |
|
Parent Case Info
This is a Continuation-in-Part application of Ser. No. 551,459 filed Feb. 20, 1975, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3840516 |
Umezawa et al. |
Oct 1974 |
|
Non-Patent Literature Citations (1)
Entry |
Umezawa, et al; Chem. Abst. 80, 144396h 1974. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
551459 |
Feb 1975 |
|